Clinical Trials
5 trialsNCT04337177 2026-05-11
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Active not recruiting
NCT06521567 2025-11-12
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT04634357 2025-04-09
ARYA-2
Eureka Therapeutics Inc.
Phase 1/2 Recruiting
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT01125800 2017-03-20
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Novartis
Phase 1/2 Completed